Simcere Pharmaceutical Group (ADR)  

(Public, NYSE:SCR)   Watch this stock  
Find more results for SCR
9.32
+0.03 (0.32%)
May 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 9.20 - 9.37
52 week 7.25 - 9.59
Open 9.20
Vol / Avg. 6,918.00/24,799.00
Mkt cap 492.75M
P/E 25.78
Div/yield     -
EPS 0.36
Shares 52.87M
Beta 0.81
Inst. own 2%
Aug 5, 2013
Q2 2013 Simcere Pharmaceutical Group Earnings Release Add to calendar
May 29, 2013
Simcere Pharmaceutical Group at Nomura Pan-Asia Technology Forum - 2:30AM EDT - Add to calendar
May 9, 2013
Q1 2013 Simcere Pharmaceutical Group Earnings Conference Call - Webcast
May 6, 2013
Q1 2013 Simcere Pharmaceutical Group Earnings Release
Mar 7, 2013
Q4 2012 Simcere Pharmaceutical Group Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin 2.37% 7.44%
Operating margin 6.25% 7.03%
EBITD margin - 12.87%
Return on average assets 1.45% 4.37%
Return on average equity 4.34% 9.07%
Employees 4,334 -
Carbon Disclosure Rating - -

Address

No.699-18 Xuan Wu Avenue Xuan Wu District
NANJING, JNG 210042
China
+86-25-85566666 (Phone)
+86-25-85471729 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Simcere Pharmaceutical Group is a holding company. The Company principally engaged in the research, development, manufacture and distribution of pharmaceutical and vaccine products in the People�s Republic of China. As of December 31, 2011, it manufactured and sold 47 pharmaceutical products and is the distributor of two additional pharmaceutical products that are marketed under its brand names. It markets and sells its products directly or indirectly to approximately 1,106 pharmaceutical distributors who in turn sell these products to other distributors, hospitals and retail pharmacies throughout China. As of March 31, 2012, italso had over 10 product candidates in various stages of development, including treatments for cancer and cardiovascular diseases. It has obtained approvals from the State Food and Drug Administration (SFDA) to manufacture and sell over 223 other products. In December 2011, the Company acquired an additional 9.80% interest in Jilin Boda Pharmaceutical Co., Ltd.

Officers and directors

Jinsheng Ren Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Hongquan Liu Chief Executive Officer, Executive Director
Age: 53
Bio & Compensation  - Reuters
Yushan Wan Acting Chief Financial Officer, Corporate Controller
Age: 42
Bio & Compensation  - Reuters
Hong Zhao Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Jindong Zhou Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Xiaojin Yin Senior Vice President - Research & Development
Age: 53
Bio & Compensation  - Reuters
Peng Wang Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Jialun Tian Vice President - Hospital Sales
Age: 47
Bio & Compensation  - Reuters
Quanfu Feng Vice President - Marketing
Age: 47
Bio & Compensation  - Reuters
Jie Liu D'Elia Vice President
Age: 38
Bio & Compensation  - Reuters